These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells. Walters ZS; Villarejo-Balcells B; Olmos D; Buist TW; Missiaglia E; Allen R; Al-Lazikani B; Garrett MD; Blagg J; Shipley J Oncogene; 2014 Feb; 33(9):1148-57. PubMed ID: 23435416 [TBL] [Abstract][Full Text] [Related]
3. PAX3-FOXO1 drives miR-486-5p and represses miR-221 contributing to pathogenesis of alveolar rhabdomyosarcoma. Hanna JA; Garcia MR; Lardennois A; Leavey PJ; Maglic D; Fagnan A; Go JC; Roach J; Wang YD; Finkelstein D; Hatley ME Oncogene; 2018 Apr; 37(15):1991-2007. PubMed ID: 29367756 [TBL] [Abstract][Full Text] [Related]
4. ACTA1 is inhibited by PAX3-FOXO1 through RhoA-MKL1-SRF signaling pathway and impairs cell proliferation, migration and tumor growth in Alveolar Rhabdomyosarcoma. Hu Q; Zhu L; Li Y; Zhou J; Xu J Cell Biosci; 2021 Jan; 11(1):25. PubMed ID: 33509264 [TBL] [Abstract][Full Text] [Related]
5. Sphingosine Induces Apoptosis and Down-regulation of Ahn EH; Lee MB; Seo DJ; Lee J; Kim Y; Gupta K Anticancer Res; 2018 Jan; 38(1):71-76. PubMed ID: 29277758 [TBL] [Abstract][Full Text] [Related]
15. Fusion transcriptome profiling provides insights into alveolar rhabdomyosarcoma. Xie Z; Babiceanu M; Kumar S; Jia Y; Qin F; Barr FG; Li H Proc Natl Acad Sci U S A; 2016 Nov; 113(46):13126-13131. PubMed ID: 27799565 [TBL] [Abstract][Full Text] [Related]
16. Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma. Böhm M; Wachtel M; Marques JG; Streiff N; Laubscher D; Nanni P; Mamchaoui K; Santoro R; Schäfer BW J Clin Invest; 2016 Nov; 126(11):4237-4249. PubMed ID: 27760049 [TBL] [Abstract][Full Text] [Related]
17. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas. Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794 [TBL] [Abstract][Full Text] [Related]
18. PAX-FOXO1 fusion status in children and adolescents with alveolar rhabdomyosarcoma: Impact on clinical, pathological, and survival features. Raze T; Lapouble E; Lacour B; Guissou S; Defachelles AS; Gaspar N; Delattre O; Pierron G; Desandes E Pediatr Blood Cancer; 2023 Apr; 70(4):e30228. PubMed ID: 36722003 [TBL] [Abstract][Full Text] [Related]
19. Piperacetazine Directly Binds to the PAX3::FOXO1 Fusion Protein and Inhibits Its Transcriptional Activity. Nakazawa K; Shaw T; Song YK; Kouassi-Brou M; Molotkova A; Tiwari PB; Chou HC; Wen X; Wei JS; Deniz E; Toretsky JA; Keller C; Barr FG; Khan J; Üren A Cancer Res Commun; 2023 Oct; 3(10):2030-2043. PubMed ID: 37732905 [TBL] [Abstract][Full Text] [Related]
20. Novel PAX3::MAML3 Fusion Identified in Alveolar Rhabdomyosarcoma, Using DNA Methylation Profiling to Expand the Genetic Spectrum of "Fusion-Positive" Cases. Dermawan JK; Malik F; Gross JM; Baraban E; Pratilas C; Mneimneh W; Trucco M; Sun W; Barr FG; D'Almeida Costa F; Fritchie KJ Mod Pathol; 2024 Nov; 37(11):100594. PubMed ID: 39147032 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]